OpGen Inc (OPGN)

[chillswills37]

$OPGN Chair Wm. Rhodes adds another notch to his career résumé.

For those who harbour doubts about a near term bright future for OpGen, Inc., please read this post through and click on the links. It may put those doubts to rest. To put it squarely, a man of this calibre, breathtaking accomplishments, and elevated status wouldn't be in OPGN for mere lunch money.

Item 1
Get to know William "Bill" Rhodes and his attainments in business, academia, and science.

A résumé extraordinaire. Highly recommended reading.
https://cytosmart.com/william-e-rhodes-iii

Three snippets, teasers, from the full article:

Mr. William E. Rhodes, III, served as Chairman of the Supervisory Board of Curetis N.V. since the IPO in 2015. Curetis merged with OpGen Inc (NASDAQ:OPGN) in 2020, and Mr. Rhodes now serves as Chairman of the Board of OpGen.

He (Rhodes) originated eleven U.S. patents for novel topical drugs and has been a lecturer on entrepreneurship in life sciences at Cornell University, and served as an Adjunct Professor teaching courses in innovation technology and M&A at Seton Hall University and San Jose State University.

During his 14-year career at Becton, Dickinson and Company (BD, 1998-2012), Mr. Rhodes held several senior leadership positions, including roles as Worldwide President of BD Biosciences (2009-2011), a greater than US$1 billion revenue segment of BD. Mr. Rhodes was also an Executive Officer of BD, and was responsible for corporate strategy and merger and acquisition functions for all of BD’s businesses. Furthermore, he founded BD Ventures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior business development positions at Johnson & Johnson and Pfizer Inc."
--------------------
Item 2
Breaking news in re: William "Bill" Rhodes
https://www.wfmz.com/news/pr_newswire/pr_newswire_business/gen-incode-appoints-new-chairman/article_247ba535-9701-5fdb-8492-75908dc999a2.html

OXFORD, England, Jan. 7, 2021 /PRNewswire/ -GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021.

Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and Diagnostics industry across NASDAQ, Euronext and AIM-listed public companies, as well as private companies in the U.S., UK and Europe. He is a strategic and commercially focused leader with significant experience at the board level across large and small companies, with specific focus in recent years on diagnostic companies in the small to mid-cap space.

Bill holds a Bachelor's of Science and Masters in International Business and served as Worldwide President of Becton Dickinson's Biosciences business and was Becton Dickinson's Corporate Executive Officer for Strategy and Corporate Development. Bill currently also serves as Chairman at OpGen Inc, Omega Diagnostics Group PLC and CytoSMART Technologies, and had been the Chairman of the Supervisory Board of Curetis until its combination with OpGen. He also currently sits on the Board of Paramit Corp. in Morgan Hill, California.

Bill has substantial corporate and commercial expertise and experience including fundraising, IPOs, mergers, acquisitions and divestment, with over $1 billion of fundraising and M&A transactions accomplished in the UK, Europe and the U.S.

He is active with his alma mater, Cornell University, mentoring life sciences startups there as a Senior Executive in Residence, and serves as an advisor to Altaris Capital Partners, a large U.S.-based healthcare private equity fund.

Matthew Walls, Chief Executive Officer, said: "We are delighted to welcome Bill to the Company and Board. Bill brings an international and U.S. focus to strengthen the Board and joins us at an exciting time as we prepare to execute the next steps in the Company's global growth strategy."
###